Zymeworks Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDZymeworks Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 63), indicating performance broadly in line with the market. Earnings contraction of 97% provides fundamental context to the price action. Investors should exercise caution due to high volatility (53% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $24.08 | +10.96% | ABOVE |
| 50 SMA | $24.95 | +7.10% | ABOVE |
| 100 SMA | $24.89 | +7.35% | ABOVE |
| 150 SMA | $24.85 | +7.53% | ABOVE |
| 200 SMA | $23.34 | +14.49% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ZYME in an uptrend right now?
ZYME has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ZYME is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ZYME overbought or oversold?
ZYME's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is ZYME outperforming the market?
ZYME has a Relative Strength (RS) Rating of 63 out of 99. ZYME is performing about average compared to the market.
Where is ZYME in its 52-week range?
ZYME is trading at $26.72, which is 90% of its 52-week high ($29.75) and 83% above its 52-week low ($11.51).
How volatile is ZYME?
ZYME has a Beta of 0.78 and 52-week volatility of 53%. It's less volatile than the S&P 500 - generally more stable.